ECP effective in the long-term

Article

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Dr Lima and colleagues conducted a long-term retrospective study of ECP in refractory glaucomas that included 539 eyes of 485 patients. Each subject underwent one ECP and were followed-up for a minimum five-year period, and retrospectively reviewed. Limbal or pars plana ECP was performed for 210 degrees with scleral depression of the ciliary body.Preoperative IOP was 37.9±6.4 mmHg, diminishing to 15.7±8.5 mmHg. The average number of surgeries preoperatively was 2.2 and the mean number of preoperative medications was 3.9±0.6, reducing postoperatively to 1.5±1.1. Success at one and five years postoperatively (defined as IOP between 5 and 22 mmHg) was 92.6% and 78.8%, respectively. Complications included fibrin exudates (21.5%), failed corneal graft (19.7%), hyphaema (10.7%), immediate postoperative IOP spike (9.8%), choroidal detachment (5.8%), phthisis (2.4%), retinal detachment (1.5%) and hypotony (1.3%).

The authors of this study believe that the results demonstrate the effectiveness of ECP as a long-term management approach for refractory glaucoma and recommend that it be considered as a first-line treatment.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.